Related Experiment Video
Updated: Jun 4, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Frontotemporal dementias: Recent advances and current controversies
Cristian E Leyton1, John R Hodges
1Neuroscience Research Australia (NeuRA), The University of New South Wales, Sydney, Australia.
Annals of Indian Academy of Neurology
|March 4, 2011
Summary
Frontotemporal dementia (FTD) presents diverse clinical syndromes, including behavioral, semantic, and nonfluent aphasia variants. Recent advances in diagnostics offer improved early detection for these challenging neurodegenerative conditions.
Area of Science:
- Neurology
- Neuroscience
- Pathology
Background:
- Frontotemporal dementia (FTD) encompasses heterogeneous neurodegenerative syndromes.
- Characterized by frontal and temporal lobe atrophy, FTD includes behavioral variant (bv-FTD), semantic dementia (SD), and progressive nonfluent aphasia (PNFA).
- The logopenic/phonological (LPA) variant, associated with Alzheimer's pathology, is a recently identified subtype.
Purpose of the Study:
- To review recent insights and ongoing debates in the field of Frontotemporal dementia.
- To highlight the diagnostic challenges posed by clinical, pathological, and genetic overlaps with other neurodegenerative diseases.
- To discuss the potential of new diagnostic tools for early FTD detection.
Main Methods:
- Review of current literature on Frontotemporal dementia.
- Analysis of diagnostic challenges and advancements.
- Discussion of emerging biomarkers and cognitive tests.
Main Results:
- FTD diagnosis is complicated by overlaps with conditions like motoneuron disease (MND) and corticobasal degeneration (CBD).
- Genetic mutations (tau, progranulin) can lead to inconsistent clinical phenotypes.
- New cognitive tests and molecular pathology advancements improve understanding and diagnostic accuracy.
Conclusions:
- Accurate biomarkers for early diagnosis of FTD are becoming increasingly feasible.
- Improved understanding of FTD subtypes and pathology aids in differential diagnosis.
- Continued research is crucial for addressing the complexities of FTD syndromes.
Related Concept Videos
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...